Mutual contribution of Pten and estrogen to endometrial carcinogenesis in a Pten loxP/loxP mouse model

International Journal of Gynecological Cancer

Volumn 21, Issue 8, 2011, Pages 1343-1349

  Saito, Fumitaka ^a   Tashiro, Hironori ^a   To, Yoko ^a   Ohtake, Hideyuki ^a   Ohba, Takashi ^a   Suzuki, Akira ^b   Katabuchi, Hidetaka ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Endometrial carcinoma; Estrogen; Mouse model; Pten

Indexed keywords

ADENOVIRUS VECTOR; CRE RECOMBINASE; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; ESTROGEN; INTEGRASE; PTEN PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; ENDOMETRIUM; ENDOMETRIUM CARCINOGENESIS; ENDOMETRIUM CARCINOMA; ENDOMETRIUM CELL; ENDOMETRIUM HYPERPLASIA; ENZYME ACTIVATION; EPITHELIUM CELL; FEMALE; GENE INACTIVATION; IMMUNOHISTOCHEMISTRY; LOXP SITE; MOUSE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; UTERUS WEIGHT; 129 MOUSE; ADENOVIRUS; ANIMAL; C57BL MOUSE; CARCINOMA; DISEASE COURSE; DISEASE MODEL; ENDOMETRIUM TUMOR; EPITHELIUM; GENETICS; METABOLISM; ORGAN SIZE; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; UTERUS;

ADENOVIRIDAE; ANIMALS; CARCINOMA; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; EPITHELIUM; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; IMMUNOHISTOCHEMISTRY; INTEGRASES; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, TRANSGENIC; ORGAN SIZE; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; UTERUS;

EID: 84857489234     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31822d2a8a     Document Type: Article

References (25)

1. Ellenson LH, Wu TC. Focus on endometrial and cervical cancer. Cancer Cell. 2004;5:533-538. (Pubitemid 38748915)
2. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006;24:4783-4791. (Pubitemid 46630943)
3. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997;57:3935-3940. (Pubitemid 27427679)
4. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943-1947. (Pubitemid 27148818)
5. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst. 2000;92:924-931. (Pubitemid 30429193)
6. Levine RL, Cargile CB, Blazes MS, et al. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrial carcinoma. Cancer Res. 1998;58:3254-3258. (Pubitemid 28371061)
7. Konopka B, Paszko Z, Janiec-Jankowska A, et al. Assessment of the quality and frequency of mutations occurrence in PTEN gene in endometrial carcinomas and hyperplasias. Cancer Lett. 2002;178:43-51. (Pubitemid 34159240)
8. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell. 2000;100:387-390.
9. Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A. 1999;96:1563-1568. (Pubitemid 29098491)
10. Kanamori Y, Kigawa J, Itamochi H, et al. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin Cancer Res. 2001;7:892-895. (Pubitemid 32708726)
11. Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial carcinoma. Endocr Relat Cancer. 2003;10:203-208. (Pubitemid 36758649)
12. Creasman WT. Estrogen and cancer. Gynecol Oncol. 2002;86:1-9.
13. Suzuki A, Yamaguchi MT, Ohteki T, et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity. 2001;14:523-534. (Pubitemid 32520864)
14. Suzuki A, de la Pompa JL, Stambolic V, et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol. 1998;22:1169-1178. (Pubitemid 28494715)
15. Tavassoli FA, Devilee P. Pathology and genetics of tumors of the breast and female genital organs. World Health Organization Classification of Tumors. Lyon, France: IARC Press; 2003:217-232.
16. Begum M, Tashiro H, Katabuchi H, et al. Neonatal estrogenic exposure suppresses PTEN-related endometrial carcinogenesis in recombinant mice. Lab Invest. 2006;86:286-296. (Pubitemid 43276960)
17. Mutter GL. Pten, a protean tumor suppressor. Am J Pathol. 2001;158:1895-1898. (Pubitemid 32545170)
18. Kong D, Suzuki A, Zou TT, et al. PTEN1 is frequently mutated in primary endometrial carcinomas. Nat Genet. 1997;17:143-144.
19. Schneider HP. HRT and cancer risks. Maturitas. 2002;43:35-52.
20. Mutter GL, Lin MC, Fitzgerald JT, et al. Changes in endometrial PTEN expression throughout the human menstrual cycle. J Clin Endocrinol Metab. 2000;85:2334-2338. (Pubitemid 32269265)
21. Vilgelm A, Lian Z, Wang H, et al. Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/j mice. Cancer Res. 2006;66:3375-3380.
22. Buring JE, Bain CJ, Ehrmann RL. Conjugated estrogen use and risk of endometrial cancer. Am J Epidemiol. 1986;124:434-441. (Pubitemid 16047360)
23. Salama SA, Kamel M, Awad M, et al. Catecholestrogens induce oxidative stress and malignant transformation in human endometrial glandular cells: protective effect of catechol-O-methyltransferase. Int J Cancer. 2008;123:1246-1254.
24. Wang Z, Wijewickrama GT, Peng KW, et al. Estrogen receptor α enhances the rate of oxidative DNA damage by targeting an equine estrogen catechol metabolite to the nucleus. J Biol Chem. 2009;284:8633-8642.
25. Turbiner J, Moreno-Bueno G, Dahiya S, et al. Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen. Mod Pathol. 2008;21:925-936.